Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Ionis Pharmaceuticals, Inc. (IONS)

45.36   -0.9 (-1.95%) 09-29 16:00
Open: 47 Pre. Close: 46.26
High: 47 Low: 45.22
Volume: 1,338,005 Market Cap: 6,501(M)

Technical analysis

as of: 2023-09-29 4:28:22 PM
Short-term rate:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Mid-term rate:       
Target: Six months: 55.73     One year: 65.09
Support: Support1: 42.37    Support2: 39.08
Resistance: Resistance1: 47.71    Resistance2: 55.73
Pivot: 43.72
Moving Average: MA(5): 45.53     MA(20): 42.85
MA(100): 40.76     MA(250): 39.83
MACD: MACD(12,26): 1.3     Signal(9): 1
Stochastic oscillator: %K(14,3): 80.2     %D(3): 85
RSI: RSI(14): 64
52-week: High: 47.74  Low: 32.68
Average Vol(K): 3-Month: 972 (K)  10-Days: 1,238 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ IONS ] has closed below upper band by 25.1%. Bollinger Bands are 53.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 47.02 - 47.34 47.34 - 47.6
Low: 44.62 - 44.93 44.93 - 45.18
Close: 44.92 - 45.41 45.41 - 45.81

Company Description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Headline News

Mon, 02 Oct 2023
Q3 2023 EPS Estimates for Ionis Pharmaceuticals, Inc. (NASDAQ ... - MarketBeat

Fri, 29 Sep 2023
Raymond James Initiates Coverage of Ionis Pharmaceuticals (IONS ... - Nasdaq

Thu, 28 Sep 2023
Eplontersen Phase 3 results published in JAMA show consistent ... - PR Newswire

Thu, 28 Sep 2023
Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX ... - Nasdaq

Wed, 27 Sep 2023
Ionis enters agreement with Roche for two novel RNA-targeted ... - PR Newswire

Tue, 26 Sep 2023
Analyst Rating: Will Ionis Pharmaceuticals Inc (IONS) Stock Lead the Market? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 143 (M)
Shares Float 142 (M)
% Held by Insiders 0.7 (%)
% Held by Institutions 95 (%)
Shares Short 9,290 (K)
Shares Short P.Month 9,210 (K)

Stock Financials

EPS -2.18
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.99
Profit Margin (%) -49.1
Operating Margin (%) -74.5
Return on Assets (ttm) -10.9
Return on Equity (ttm) -58.8
Qtrly Rev. Growth 40.7
Gross Profit (p.s.) -1.8
Sales Per Share 4.39
EBITDA (p.s.) -3.18
Qtrly Earnings Growth 0
Operating Cash Flow -456 (M)
Levered Free Cash Flow -269 (M)

Stock Valuations

PE Ratio -20.91
PEG Ratio 0.2
Price to Book value 15.17
Price to Sales 10.31
Price to Cash Flow -14.26

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.